Marianne E Pavel1, Simron Singh2, Jonathan R Strosberg3, Lida Bubuteishvili-Pacaud4, Evgeny Degtyarev4, Maureen P Neary5, Carlo Carnaghi6, Jiri Tomasek7, Edward Wolin8, Markus Raderer9, Harald Lahner10, Juan W Valle11, Rodney Pommier12, Eric Van Cutsem13, Margot E T Tesselaar14, Gianfranco Delle Fave15, Roberto Buzzoni16, Matthias Hunger17, Jennifer Eriksson18, David Cella19, Jean-François Ricci20, Nicola Fazio21, Matthew H Kulke22, James C Yao23. 1. Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany; Department of Medicine 1, Division of Endocrinology, Universitätsklinikum Erlangen, Erlangen, Germany. 2. Division of Medical Oncology & Hematology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada. Electronic address: simron.singh@sunnybrook.ca. 3. Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA. 4. Novartis Pharma AG, Basel, Switzerland. 5. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. 6. Oncology Unit, Humanitas Clinical and Research Centre, Rozzano, Italy. 7. Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno, Czech Republic. 8. Department of Medical Oncology, Montefiore Einstein Center for Cancer Care, Bronx, NY, USA. 9. Department of Internal Medicine I, Division of Oncology, Klinik f Innere Medizin I, AKH, Vienna, Austria. 10. Klinik für Endokrinologie und Stoffwechselerkrankungen, Universitaetsklinikum Essen, Zentrum f Innere Medizin, Essen, Germany. 11. Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK. 12. Division of Surgical Oncology, Oregon Health & Science University, Portland, OR, USA. 13. University Hospitals Leuven, and KU Leuven, Digestive Oncology, Leuven, Belgium. 14. Department of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, Netherlands. 15. Medical-Surgical Sciences and Translational Medicine, Azienda Ospedaliera Sant'Andrea - Università La Sapienza, Rome, Italy. 16. S C Day Hospital e Terapia Ambulatoriale Oncologica, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy. 17. Mapi, Munich, Germany. 18. Mapi, Stockholm, Sweden. 19. Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA. 20. Wellmera AG, Basel, Switzerland. 21. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, Milan, Italy. 22. Medical Oncology and Solid Tumor Oncology, Dana Farber Cancer Institute, Boston, MA, USA. 23. Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract
BACKGROUND: In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report the health-related quality of life (HRQOL) secondary endpoint. METHODS: RADIANT-4 is a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial done in 97 centres in 25 countries worldwide. Adults (aged ≥18 years) were eligible for the study if they had pathologically confirmed, advanced (unresectable or metastatic), non-functional, well-differentiated (grade 1 or 2) NETs of lung or gastrointestinal origin. Patients were randomly allocated (2:1) using block randomisation (block size of three) by an interactive voice response system to receive oral everolimus (10 mg per day) or placebo, both with best supportive care, with stratification by tumour origin, WHO performance status, and previous somatostatin analogue treatment. HRQOL was assessed with the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire at baseline (visit 2, day 1), every 8 weeks (± 1 week) during the study for the first 12 months after randomisation, and every 12 weeks thereafter until study drug discontinuation. The primary endpoint, reported previously, was progression-free survival assessed by central review; HRQOL was a prespecified secondary endpoint. The prespecified secondary outcome measure was time to definitive deterioration (≥7 points) in FACT-G total score. Analyses were done on the full analysis set, consisting of all randomised patients, by intention to treat. Only data obtained while receiving the randomly allocated treatment were included in this analysis. Enrolment for RADIANT-4 was completed on Aug 23, 2013, but the trial is ongoing pending final analysis of the key secondary endpoint of overall survival. This trial is registered with ClinicalTrials.gov, number NCT01524783. FINDINGS:Between April 3, 2012, and Aug 23, 2013, 302 patients were enrolled; 205 were randomly allocatedeverolimus and 97 were assigned placebo. At baseline, 193 (94%) of 205 patients assigned everolimus and 95 (98%) of 97 allocated placebo had completed either fully or partly the FACT-G questionnaire; at week 48, 70 (83%) of 84 patients assigned everolimus and 22 (85%) of 26 allocated placebo completed FACT-G. Median time to definitive deterioration in FACT-G total score was 11·27 months (95% CI 9·27-19·35) with everolimus and 9·23 months (5·52-not estimable) with placebo (adjusted hazard ratio 0·81, 95% CI 0·55-1·21; log-rank p=0·31). INTERPRETATION:HRQOL was maintained for patients with advanced, non-functional, gastrointestinal or lung NETs, with no relevant differences noted between the everolimus and placebo groups. In view of the previous RADIANT-4 findings of longer progression-free survival with everolimus, our findings suggest that everolimus delays disease progression while preserving overall HRQOL, even with the usual toxic effects related to active targeted drug treatment for cancer. FUNDING: Novartis Pharmaceuticals.
RCT Entities:
BACKGROUND: In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report the health-related quality of life (HRQOL) secondary endpoint. METHODS: RADIANT-4 is a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial done in 97 centres in 25 countries worldwide. Adults (aged ≥18 years) were eligible for the study if they had pathologically confirmed, advanced (unresectable or metastatic), non-functional, well-differentiated (grade 1 or 2) NETs of lung or gastrointestinal origin. Patients were randomly allocated (2:1) using block randomisation (block size of three) by an interactive voice response system to receive oral everolimus (10 mg per day) or placebo, both with best supportive care, with stratification by tumour origin, WHO performance status, and previous somatostatin analogue treatment. HRQOL was assessed with the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire at baseline (visit 2, day 1), every 8 weeks (± 1 week) during the study for the first 12 months after randomisation, and every 12 weeks thereafter until study drug discontinuation. The primary endpoint, reported previously, was progression-free survival assessed by central review; HRQOL was a prespecified secondary endpoint. The prespecified secondary outcome measure was time to definitive deterioration (≥7 points) in FACT-G total score. Analyses were done on the full analysis set, consisting of all randomised patients, by intention to treat. Only data obtained while receiving the randomly allocated treatment were included in this analysis. Enrolment for RADIANT-4 was completed on Aug 23, 2013, but the trial is ongoing pending final analysis of the key secondary endpoint of overall survival. This trial is registered with ClinicalTrials.gov, number NCT01524783. FINDINGS: Between April 3, 2012, and Aug 23, 2013, 302 patients were enrolled; 205 were randomly allocated everolimus and 97 were assigned placebo. At baseline, 193 (94%) of 205 patients assigned everolimus and 95 (98%) of 97 allocated placebo had completed either fully or partly the FACT-G questionnaire; at week 48, 70 (83%) of 84 patients assigned everolimus and 22 (85%) of 26 allocated placebo completed FACT-G. Median time to definitive deterioration in FACT-G total score was 11·27 months (95% CI 9·27-19·35) with everolimus and 9·23 months (5·52-not estimable) with placebo (adjusted hazard ratio 0·81, 95% CI 0·55-1·21; log-rank p=0·31). INTERPRETATION: HRQOL was maintained for patients with advanced, non-functional, gastrointestinal or lung NETs, with no relevant differences noted between the everolimus and placebo groups. In view of the previous RADIANT-4 findings of longer progression-free survival with everolimus, our findings suggest that everolimusdelays disease progression while preserving overall HRQOL, even with the usual toxic effects related to active targeted drug treatment for cancer. FUNDING: Novartis Pharmaceuticals.
Authors: E Charton; B Cuer; F Cottone; F Efficace; C Touraine; Z Hamidou; F Fiteni; F Bonnetain; M-C Woronoff-Lemsi; C Bascoul-Mollevi; A Anota Journal: Qual Life Res Date: 2019-11-27 Impact factor: 4.147
Authors: Jonathan Strosberg; Edward Wolin; Beth Chasen; Matthew Kulke; David Bushnell; Martyn Caplin; Richard P Baum; Pamela Kunz; Timothy Hobday; Andrew Hendifar; Kjell Oberg; Maribel Lopera Sierra; Thomas Thevenet; Ines Margalet; Philippe Ruszniewski; Eric Krenning Journal: J Clin Oncol Date: 2018-06-07 Impact factor: 44.544
Authors: Jeffery Chakedis; Eliza W Beal; Alexandra G Lopez-Aguiar; George Poultsides; Eleftherios Makris; Flavio G Rocha; Zaheer Kanji; Sharon Weber; Alexander Fisher; Ryan Fields; Bradley A Krasnick; Kamran Idrees; Paula Marincola-Smith; Clifford Cho; Megan Beems; Timothy M Pawlik; Shishir K Maithel; Carl R Schmidt; Mary Dillhoff Journal: J Gastrointest Surg Date: 2018-10-17 Impact factor: 3.452
Authors: Reto M Kaderli; Marko Spanjol; Attila Kollár; Lukas Bütikofer; Viktoria Gloy; Rebecca A Dumont; Christian A Seiler; Emanuel R Christ; Piotr Radojewski; Matthias Briel; Martin A Walter Journal: JAMA Oncol Date: 2019-04-01 Impact factor: 31.777